NasdaqGS:MDGLBiotechs
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s Strong Q2 Sales and EU Approval
If you are reevaluating your position in Madrigal Pharmaceuticals (MDGL) after its latest quarterly update, you are not alone. The company surprised markets by reporting stronger-than-expected second-quarter sales, driven by its flagship liver disease drug Rezdiffra. Over 23,000 patients are already using the treatment, and the recent European Union approval appears to have reinforced Madrigal’s reputation as a front-runner in the MASH therapy market.
Momentum has been clearly building for...